Teva Cites BG-12 Safety in Asking FDA to Add MS Reviews

Teva Pharmaceutical Industries Ltd. asked U.S. regulators for more scrutiny before they approve any new multiple sclerosis drugs as it tries to block Biogen Idec Inc.’s BG-12 oral treatment from entering the market.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.